Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0021843 (bowel obstruction)
 9,927 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Three patients with the carcinoid syndrome received intravenous somatostatin (3.5 micrograms/min) for one day; intravenous salmon calcitonin (8 IU/hr) for one day; subcutaneous salmon calcitonin (100 IU three times daily) for ten days; and subcutaneous octreotide (150 micrograms three times daily) for ten days. Octreotide (SMS-201.995) is a stable analogue of somatostatin. There was a five-day washout period between each treatment. During each of these treatments, reductions in the numbers of daily flushes and bowel movements, stool weight, and urinary 5-hydroxyindoleacetic acid (5-HIAA) levels were observed. Relief of cramping abdominal pains was also reported. Patients 1 and 3 chose to continue receiving the subcutaneous calcitonin and patient 2 chose the octreotide. Patient 1 (aged 67 years) reported relief of symptoms for five months until she developed an intestinal obstruction as a result of tumor infiltration. Patient 3 (aged 67 years) has received the calcitonin for about 16 months with relief of symptoms and reduced urinary 5-HIAA levels. Patient 2 (aged 57 years) has continued octreotide treatment for one year and reports relief of symptoms.
 ...
PMID:Treatment of the carcinoid syndrome with somatostatin, salmon calcitonin, or octreotide. 137 97

The effect of subcutaneous somatostatin analogue SMS 201-995 (Sandoz Pharmaceuticals Corp., East Hanover, NJ) was investigated in a patient with acute postoperative secretory diarrhea. The patient was hospitalized with bowel obstruction caused by a descending colon adenocarcinoma. One week after left hemicolectomy and transverse colostomy, watery colostomy output, which exceeded 10 L per day developed. Jejunal perfusion studies suggested that the patient's diarrhea was caused by abnormal net secretion of water and electrolytes by the small intestine. Circulating levels of various peptide hormones were normal with the exception of elevated level of pancreatic polypeptide. SMS 201-995 administration reduced colostomy output and normalized many of the abnormalities found during jejunal perfusion. These results indicate that the patient's acute secretory diarrhea, occurring after large intestinal obstruction, originated in the small intestine and that SMS 201-995 can be used to manage this unusual severe postoperative problem.
 ...
PMID:Severe posthemicolectomy diarrhea: evaluation and treatment with SMS 201-995. 239 36

An 8-week-old infant presented with vomiting and failure to thrive due to small bowel obstruction caused by a diffusely enlarged pancreas. Surgical bypass of the obstruction was followed by secretory diarrhea, hypokalemia, and dehydration. Plasma vasoactive intestinal peptide (VIP) (823pg/ml), pancreatic polypeptide (4,500 pg/ml), and neurotensin (680 pg/ml) concentrations were markedly elevated. No neoplastic process was identified. Therapy with the long-acting somatostatin analogue SMS 201-995 was followed by decline in VIP concentrations (900 to 200-300 pg/ml), decrease in stool frequency, and normalization of serum electrolytes. During 12 months of somatostatin analogue therapy, length and weight progressed along the 3rd percentile on the Tanner growth chart.
 ...
PMID:Watery diarrhea, hypokalemia, achlorhydria syndrome in an infant: effect of the long-acting somatostatin analogue SMS 201-995 on the disease and linear growth. 289 8